Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 1/20 | 0.49 |
| ▸ | GAK | O14976 | 10/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 7/20 | 0.48 |
| ▸ | COQ8A | Q8NI60 | 7/20 | 0.48 |
| ▸ | NLK | Q9UBE8 | 7/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14155006 | 0.89 | CCNB2 (0.47) | GAKRIPK2COQ8ANLKIDO1 | |
| SCHEMBL4917317 | 0.84 | GAK (0.53) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL12330553 | 0.83 | TDO2 (0.54) | PTK6GAKIDO1TDO2CCNB2 | |
| SCHEMBL4929965 | 0.79 | CCNB2 (0.50) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL2447762 | 0.79 | CCNB2 (0.60) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL4925395 | 0.79 | CCNB2 (0.54) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL2446373 | 0.77 | GAK (0.55) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL14115560 | 0.76 | TNIK (0.44) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL14115561 | 0.76 | CCNB2 (0.54) | GAKRIPK2COQ8ANLKCCNB2 | |
| SCHEMBL4936730 | 0.75 | IGF1R (0.57) | GAKRIPK2COQ8ANLKCCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8859581-B2 | Azaheterocyclic compounds as kinase inhibitors | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-1874769-B1 | NOVEL AZA- HETEROCYCLES SERVING AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176892-A1 | Anticancer agents; synergistic use; regulate and/or modulate tyrosine kinase signal transduction particularly an IGF-R1-inhibiting action; 3-[2-(3,4,5-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-ylamino]benzonitrile; reaction with arylsilylacetylene | IGF1R, IGFBP1, ERBB2 | PTK6 148/4885GAK 149/4885RIPK2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.